Patents by Inventor Kapil Mehta

Kapil Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6414115
    Abstract: The present invention relates to parasitic nematode transglutaminase proteins; to parasitic nematode transglutaminase nucleic acid molecules, including those that encode such transglutaminase proteins; to antibodies raised against such transglutaminase proteins; and to compounds that inhibit parasitic nematode transglutaminase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic nematodes.
    Type: Grant
    Filed: January 13, 1998
    Date of Patent: July 2, 2002
    Assignees: Heska Corporation, Board of Regents, The University of Texas System
    Inventors: Ramaswamy Chandrashekar, Kapil Mehta
  • Patent number: 6334999
    Abstract: To optimize the delivery of all-trans retinoic acid to lung tissue, the potential of vehiculating this drug in liposomes and delivering it via aerosol was determined. Liposomes provide a means to prevent local irritation of lung tissue, reduce pulmonary toxicity, prolong therapeutic levels, and generate high drug concentrations at the tumor sites. Therefore, the delivery of ATRA to the lung tissue in mice was accomplished by nebulization of L-ATRA. The liposomes in the aerosol were uniform, stable, and retained the drug well. The drug was effectively delivered at high concentrations to the lungs of mice and was retained at least up to 96 h after a single exposure to L-ATRA aerosols. The aerosol-delivered ATRA was biologically active as demonstrated by its ability to induce the expression of tissue-type transglutaminase. Aerosol delivery of L-ATRA offers an effective way to deliver high levels of ATRA to the lung without apparent pulmonary toxic effects.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: January 1, 2002
    Assignee: Research Development Foundation
    Inventors: Brian E. Gilbert, Ranjani Parthasarathy, Kapil Mehta
  • Patent number: 6309644
    Abstract: The present invention relates to parasitic nematode transglutaminase proteins; to parasitic nematode transglutaminase nucleic acid molecules, including those that encode such transglutaminase proteins; to antibodies raised against such transglutaminase proteins; and to compounds that inhibit parasitic nematode transglutaminase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic nematodes. This invention also relates to the surprising discovery that parasitic nematode transglutaminase proteins have protein disulfide isomerase activity. Accordingly, this invention relates further to inhibitors of the protein disulfide isomerase activity of said transglutaminases.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: October 30, 2001
    Assignees: Heska Corporation, The Board of Regents, The University of Texas System
    Inventors: Ramaswamy Chandrashekar, Kapil Mehta
  • Patent number: 6200597
    Abstract: A reduced-toxicity formulation of carotenoids is disclosed which is stable in an aqueous environment. The formulation includes a carotenoid, lipid arrier particles (such as liposomes), and an intercalation promoter agent (such as a triglyceride), which causes the carotenoid to be substantially uniformly distributed with the lipid in the lipid carrier particles. The molar ratio of carotenoid to lipid is greater than about 1:10. Also disclosed is a method of inhibiting the growth of cancer cells, which comprises administering to a living subject a therapeutically effective amount of a composition as described above.
    Type: Grant
    Filed: June 10, 1998
    Date of Patent: March 13, 2001
    Assignees: Board of Regents, The University of Texas System, Aronex Pharmaceuticals, Inc.
    Inventors: Kapil Mehta, Roman Perez-Soler, Gabriel Lopez-Berestein, Robert Lenk, Alan C. Hayman
  • Patent number: 5811119
    Abstract: A reduced-toxicity formulation of carotenoids is disclosed which is stable in an aqueous environment. The formulation includes a carotenoid, lipid carrier particles (such as liposomes), and an intercalation promoter agent (such as a triglyceride), which causes the carotenoid to be substantially uniformly distributed with the lipid in the lipid carrier particles. The molar ratio of carotenoid to lipid is greater than about 1:10. Also disclosed is a method of inhibiting the growth of cancer cells, which comprises administering to a living subject a therapeutically effective amount of a composition as described above.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: September 22, 1998
    Assignees: Board of Regents, the University of Texas, Aronex Pharmaceuticals, Inc.
    Inventors: Kapil Mehta, Roman Perez-Soler, Gabriel Lopez-Berestein, Robert P. Lenk, Alan C. Hayman, deceased
  • Patent number: 5457129
    Abstract: A novel method of inhibiting production of two important mediators of cellular function, tumor necrosis factor and nitric oxide, and treating a pathophysiological state characterized by an undesirable production or level of tumor necrosis factor or nitric acid. The methods of the present invention employ retinoic acid compounds. The most preferred retinoic acid is all-trans-retinoic acid.
    Type: Grant
    Filed: May 17, 1993
    Date of Patent: October 10, 1995
    Assignee: Research Development Foundation
    Inventors: Bharat B. Aggarwal, Kapil Mehta
  • Patent number: 4978654
    Abstract: A method is disclosed for treatment of disseminated fungal infection in a mammal comprising the administration of a fungicidally effective amount of Amphotericin B encapsulated in a substantially sterol-free liposome to the infected mammal. Also provided is an agent for treatment of disseminated fungal infection in a mammal comprising Amphotericin B encapsulated in a liposome which consists essentially of lipids other than sterols.
    Type: Grant
    Filed: January 12, 1987
    Date of Patent: December 18, 1990
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gabriel Lopez-Berestein, Victor Fainstein, Evan M. Hersh, Roy L. Hopfer, Rudolph L. Juliano, Kapil Mehta, Reeta Mehta
  • Patent number: 4663167
    Abstract: Method for treatment of disseminated fungal infection in a mammal comprising the administration of a fungicidally effective amount of Amphotericin B encapsulated in a substantially sterol-free liposome to the infected mammal. Also provided is an agent for treatment of disseminated fungal infection in a mammal comprising liposome-encapsulated Amphotericin B, said liposome being comprised of lipids other than sterols.
    Type: Grant
    Filed: April 16, 1984
    Date of Patent: May 5, 1987
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Gabriel Lopez-Berestein, Victor Fainstein, Evan M. Hersh, Roy L. Hopfer, Rudolph L. Juliano, Kapil Mehta, Reeta Mehta